These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy. Ozaki H; Harada S; Takeuchi T; Kawaguchi S; Takahashi Y; Kojima Y; Ota K; Hongo Y; Ashida K; Sakaguchi M; Tokioka S; Sakamoto H; Furuta T; Tominaga K; Higuchi K Digestion; 2018; 97(3):212-218. PubMed ID: 29393194 [TBL] [Abstract][Full Text] [Related]
8. Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Yamada S; Kawakami T; Nakatsugawa Y; Suzuki T; Fujii H; Tomatsuri N; Nakamura H; Sato H; Okuyama Y; Kimura H; Yoshida N World J Gastrointest Pharmacol Ther; 2016 Nov; 7(4):550-555. PubMed ID: 27867688 [TBL] [Abstract][Full Text] [Related]
9. Comparative study: Vonoprazan and proton pump inhibitors in Sakurai K; Suda H; Ido Y; Takeichi T; Okuda A; Hasuda K; Hattori M World J Gastroenterol; 2017 Jan; 23(4):668-675. PubMed ID: 28216974 [TBL] [Abstract][Full Text] [Related]
10. The Potential Benefits of Vonoprazan as Miftahussurur M; Pratama Putra B; Yamaoka Y Pharmaceuticals (Basel); 2020 Sep; 13(10):. PubMed ID: 32998241 [No Abstract] [Full Text] [Related]
11. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis. Simadibrata DM; Syam AF; Lee YY J Gastroenterol Hepatol; 2022 Dec; 37(12):2217-2228. PubMed ID: 36181401 [TBL] [Abstract][Full Text] [Related]
12. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Murakami K; Sakurai Y; Shiino M; Funao N; Nishimura A; Asaka M Gut; 2016 Sep; 65(9):1439-46. PubMed ID: 26935876 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature. Tanabe H; Ando K; Sato K; Ito T; Goto M; Sato T; Fujinaga A; Kawamoto T; Utsumi T; Yanagawa N; Ichiishi E; Otake T; Kohgo Y; Nomura Y; Ueno N; Sugano H; Kashima S; Moriichi K; Fujiya M; Okumura T Dig Dis Sci; 2017 Nov; 62(11):3069-3076. PubMed ID: 28664410 [TBL] [Abstract][Full Text] [Related]
14. Vonoprazan: A New Potassium-Competitive Acid Blocker. St Onge E; Phillips B J Pharm Technol; 2023 Jun; 39(3):139-146. PubMed ID: 37323765 [No Abstract] [Full Text] [Related]
15. Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases. Yang X; Li Y; Sun Y; Zhang M; Guo C; Mirza IA; Li YQ Dig Dis Sci; 2018 Feb; 63(2):302-311. PubMed ID: 29282636 [TBL] [Abstract][Full Text] [Related]
17. Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication. Kusunoki M; Yuki M; Ishitobi H; Kobayashi Y; Nagaoka M; Takahashi Y; Fukuba N; Komazawa Y; Shizuku T; Kinoshita Y Intern Med; 2019 Jun; 58(11):1549-1555. PubMed ID: 30713328 [TBL] [Abstract][Full Text] [Related]
18. Comparative Efficacy and Safety of Potassium-Competitive Acid Blockers vs. Proton Pump Inhibitors for Peptic Ulcer with or without Ouyang M; Zou S; Cheng Q; Shi X; Zhao Y; Sun M Pharmaceuticals (Basel); 2024 May; 17(6):. PubMed ID: 38931366 [TBL] [Abstract][Full Text] [Related]
19. A Novel Potassium-Competitive Acid Blocker Improves the Efficacy of Clarithromycin-containing 7-day Triple Therapy against Helicobacter pylori. Noda H; Noguchi S; Yoshimine T; Goji S; Adachi K; Tamura Y; Izawa S; Ebi M; Yamamoto S; Ogasawara N; Funaki Y; Sasaki M; Kasugai K J Gastrointestin Liver Dis; 2016 Sep; 25(3):283-8. PubMed ID: 27689190 [TBL] [Abstract][Full Text] [Related]
20. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication. Tanabe H; Yoshino K; Ando K; Nomura Y; Ohta K; Satoh K; Ichiishi E; Ishizuka A; Otake T; Kohgo Y; Fujiya M; Okumura T Ann Clin Microbiol Antimicrob; 2018 Jun; 17(1):29. PubMed ID: 29950163 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]